Kornimate/medical-research-clean huggingface dataset:
balance function in patients post corona virus disease 2019 (covid-19)

Conditions: Covid19

Summary: the purpose of this study is to describe balance deficits in patients post covid-19. the information the investigators learn may help influence balance training exercises for patients post-covid-19. participants will have a primary or secondary diagnosis of covid-19 during hospitalization and off covid-19 isolation and be receiving care in an acute inpatient hospital. following consent, participants will complete balance assessments and questionnaires about balance and dizziness in a single session. vital signs will be monitored during the session.the greatest risks of this study include shortness of breath, and a risk of falling or musculoskeletal soreness.these risks are no greater than those experienced during a usual physical therapy visit.

heart rate (hr), respiratory rate (rr), blood pressure (bp), and oxygen saturation (spo2) will be measured at rest and after all outcome measures are completed. rate of perceived exertion (rpe) (0-10 per modified borg scale) will be measured after each outcome measure. in addition, hr will be measured after each outcome measure. spo2 will be continually monitored via pulse oximetry. fraction of inspired oxygen (fio2) will be titrated per md orders. if spo2 drops below md-specified parameters, patients will first be given a 3-minute seated rest break. if spo2 recovers above md-specified parameters after rest break, activity will resume. if spo2 remains below md-specified parameters after rest break or continues to drop with activity, fio2 will be titrated to maintain spo2 within md-specified parameters.

Eligibility criteria:
inclusion criteria: * age \> 18 years * primary or secondary diagnosis of covid- 19 during hospitalization and off covid-19 isolation * receiving care in acute inpatient * ability to ambulate 20' with or without an assistive device without dropping \>10% of resting oxygen saturation (determined from existing physical therapy evaluation) * ability to stand with no more than contact guard assistance (determined from existing physical therapy evaluation) * not requiring use of mechanical ventilation * minimum resting oxygen saturation of 88% with or without supplemental oxygen * no neurological or orthopedic dysfunction that would affect balance * cognitively intact and able to follow directions and provide consent exclusion criteria: * history of 2 or more falls in the year prior to covid-19 diagnosis or history of balance dysfunction

Keywords: covid balance
video game-based therapy for arm weakness in progressive multiple sclerosis

Conditions: Primary Progressive Multiple Sclerosis; Hemiparesis

Summary: participants will receive intensive therapy through a video game in their own homes for 1 month. the game is operated by movements of the body (no controller needed) and acts like a virtual therapist. participants will agree to play the game for 30 hours. they will also receive 4 home visits from a therapist designed to increase use of their arm for daily activities that are important to them. participants will also receive a smart watch that will measure use of their weaker arm and alert them when their arm is not participating in activities. arm strength and function will be measured before and after the therapy program.

randomized waitlist control trial. one group will receive treatment immediately (50%) and the other group will receive treatment following a three-week delay (50%). group 1 will be assessed by physical/occupational therapists and rehabilitation psychologists (blinded to treatment phase) before and after the virtual gaming treatment. group 2 will receive two baseline assessments (baseline followed by three weeks of usual and customary care and then another baseline before starting the gaming treatment), and again after three weeks of virtual gaming treatment.

Eligibility criteria:
inclusion criteria: * patients who have progressive multiple sclerosis resulting in upper extremity motor impairment. * have the ability to comprehend and participate in basic elements of the therapy. * have substantial non-use in the more affected upper extremity. exclusion criteria: * are currently participating in other experimental trials. * are currently participating in additional upper extremity therapy. * experienced relapse within the past 6 months. * too frail to undergo intensive rehabilitation, * those with serious, uncontrolled medical problems.

Keywords: constraint-induced movement therapy video game virtual reality upper extremity ci therapy rehabilitation hemiparesis ms multiple sclerosis progressive multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis motor physical therapy physiotherapy occupational therapy arm hand
spot tm tattooing of biopsied axillary lymph nodes with ultrasound guided in breast cancer patients prior to surgery

Conditions: Breast Cancer

Summary: to assess feasibility and clinical utility of marking biopsied axillary lymph nodes with spot at time of biopsy.

as part of the diagnostic tests for breast cancer sometimes necessary to perform a fna or core biopsy to a suspicious axillary lymph node. presently there is no possibility to identify the examined gland at the surgery. if the gland was infected it's most important to remove it. the only technique that exists today is marking with a metal clip and the use of this technique is not profit, partly because of technical difficulties. in this trial the investigator will use a special ink which will be injected to the axillary lymph node during the biopsy and latter on the surgery the investigator will try to assess the ability to identify the marked gland.

Eligibility criteria:
inclusion criteria: * women with findings suspicious of breast cancer (or known breast cancer) who undergo axillary lymph node biopsy exclusion criteria: * inability to sign informed consent
efficacy of chronoterapy in oral surgery

Conditions: Tooth, Impacted; Trismus; Pain; Inflammatory Response

Summary: lower third molar extraction is one of the most common treatments in oral surgery practice. it is a treatment with inherent complications such as postoperative pain, swelling or trismus. in order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration. the aim of the study is to analyze if dosage modification of a non steroideal anti-inflammatory (ibuprofen) affects on postoperative pain, swelling and open mouth limitation comparing to the normal dosage.

a randomized crossover split-mouth clinical trial will be performed. after third molar extractions, patients will be prescribed ramdomly in one side wit the normal medication dosage while the contralateral side will be prescribed a modified dosage. moreover, a blood sample will be obtained to analize the inflammatory profile.

Eligibility criteria:
inclusion criteria: * age between 18 and 35 years old * bilateral retained lower third molar exclusion criteria: * nsaid allergic * contraindication for surgical removal of third molar

Keywords: third molar chronotherapy ibuprofen randomized
immunomodulation, il-1 inhibition, and postoperative incisional pain

Conditions: Pain; Inflammation

Summary: the investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. this knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.

this study will test whether administration of anakinra, an il-1 receptor antagonist, will decrease pain and improve wound healing in patients undergoing vascular or orthopedic surgical procedures. the investigators will administer two doses of anakinra via an injection under the skin, one dose one hour before surgery and a second dose on the first postoperative day (24 hours after surgery). the investigators will remove fluid from the surgical incisions using a small plastic catheter placed under skin during surgery and measure the amounts of pain- causing inflammatory mediators. the investigators will also measure the amount of pain the participant is experiencing using questions about pain intensity and by gently touching the incision to determine sensitivity of the incision site.

Eligibility criteria:
inclusion criteria: -patients 18 years of age and older presenting to the stanford preoperative evaluation clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries. exclusion criteria: patients will be excluded from participation if they have one or more of the following conditions: 1. evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count \> 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source 2. end-stage renal disease 3. a history of diabetic neuropathy 4. a malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years 5. leukopenia (white blood cell count \< 2,000/ul) 6. thrombocytopenia (platelet count \< 100,000/ul) 7. abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal) 8. a history or infection with tuberculosis, hepatitis b, hepatitis c, or human immunodeficiency virus 9. pregnant or breastfeeding

Keywords: biomarkers
clinical usefulness of virtual ablation guided catheter ablation of atrial fibrillation: prospective randomized study

Conditions: Atrial Fibrillation

Summary: radiofrequency catheter ablation is highly effective in the treatment of patients with persistent atrial fibrillation. in order to decrease the recurrence rate after catheter ablation, the investigators propose to apply 'virtual' ablation on patient-specific atria by simulating 3d atrial computer model. the investigators will test with five different set of ablation methods and find successful methods for a specific patient. then, this result will be compared to empirical catheter ablation result by randomly controlled trial.


Eligibility criteria:
inclusion criteria: * diagnosis of af patients who performed catheter ablation of atrial fibrillation due to uncontrolled pulse rate by anti-arrhythmic drug therapy. exclusion criteria: * af patients who have severe heart deformations or blood problems. * the patients who had been performed catheter ablation of atrial ablation. * the patients who missed out to recording of 3d ct, echo and electrocardiography.

Keywords: atrial fibrillation, virtual ablation, electrocardiography, electroanatomical mapping data
a gene delivery study to evaluate the safety and expression of delandistrogene moxeparvovec in participants under the age of four with duchenne muscular dystrophy (dmd)

Conditions: Duchenne Muscular Dystrophy

Summary: this open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with dmd. participants will be in the study for approximately 264 weeks.


Eligibility criteria:
inclusion criteria: * cohort a: \>=3 years of age to \<4 years of age * cohort b: \>=2 years of age to \<3 years of age * cohort c: \>6 months to \<2 years of age * cohort d: \<=6 months of age * has a definitive diagnosis of dmd prior to screening based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test * able to cooperate with age-appropriate motor assessment testing * a pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive) exclusion criteria: * exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression, within protocol-specified time limits * recombinant adeno-associated virus serotype rh74 (raarh74) antibody titers are elevated, as per protocol-specified criteria * receiving regular oral corticosteroids as a treatment for dmd or planning to receive oral corticosteroids as a treatment for dmd within 1 year of baseline * presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the investigator creates unnecessary risk for gene transfer * medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the participant's ability to comply with the protocol required testing or procedures, or compromise the participant's well-being or safety, or clinical interpretability other inclusion or exclusion criteria could apply

Keywords: dmd duchenne dystrophin gene-delivery pediatric
study to assess the immune reactivity of the liquid and lyophilized formulations of palivizumab (medi-493, synagis)

Conditions: Chronic Lung Disease

Summary: the purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab. this study will compare the number and percentage of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized formulation of palivizumab.

the approved liquid formulation of palivizumab was developed to simplify preparation of the drug before injection. both formulations of palivizumab have been shown to be bioequivalent in children 6 months of age or younger with a history of chronic lung disease. in previous studies of liquid palivizumab, immunogenicity was evaluated up to 2 months after dosing in adults, and 1 month after dosing in children. in this study, mi-cp116, immunogenicity will be evaluated between 4 and 6 months after the last dose of study drug, in order to provide data at a time point significantly distant from dosing when drug interference is minimal.

Eligibility criteria:
inclusion criteria: * medically stable child with chronic lung disease of prematurity who is ≤24 months of age at randomization or child with premature birth (gestational age ≤35 weeks or less) and who is 6 months of age or younger at randomization * written informed consent obtained from the patient's parent(s) or legal guardian(s) * the child must be able to complete the follow-up visit 4-6 months after the last dose of study drug exclusion criteria: * hospitalization at the time of randomization (unless discharge is anticipated within 3 weeks) * be receiving mechanical ventilation at the time of study entry (including cpap) * congenital heart disease (children with uncomplicated chd \[e.g., pda, small septal defect\] and children with complicated chd who are currently anatomically and hemodynamically normal can be enrolled). * mother with hiv infection (unless the child has been proven to be not infected) * life expectancy \<6 months * known allergy to ig products * acute respiratory or other acute infection or illness * previous reaction to igiv, blood products, or other foreign proteins * receipt of lyophilized palivizumab, rsv-ig iv, or other rsv-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis b ig, ivig, vzig) within 3 months prior to randomization * any previous receipt of medi-524 * participation in other investigational drug product studies
a study to evaluate gbt021601-012 single dose and multiple dose in participants with sickle cell disease (scd)

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of gbt021601, a hemoglobin s (hbs) polymerization inhibitor, in participants with scd, following single and multiple ascending doses.

this is an open-label intrapatient single dose followed by a multiple dose escalation study in at least six (6) participants with scd.

Eligibility criteria:
inclusion criteria: * male or female with scd * participants with scd ages 18 to 60 years, inclusive. * participant has provided documented informed consent. * patients with stable and close to baseline hemoglobin value * patients on hu should be on stable dose for at least 90 days prior to signing icf exclusion criteria: * patients had more than 10 voc within 12 months of screening * patients who are pregnant or nursing * patients who receive rbc transfusion therapy regularly or received an rbc transfusion for any reason within 60 days of signing the icf * hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the icf or within 24 days prior to day 1 treatment
neuro-ultrasound assessment in behcet's disease

Conditions: Behcet Syndrome

Summary: assessment of structural changes that occur in large extracranial and intracranial arteries in patients with behcet's disease

patients will be selected from rheumatology and rehabilitation inpatient and outpatient clinics in assiute university hospital patients under 16 years old, patients with hyperlipidemia, hypertension, diabetes mellitus and all other risk factors affecting blood vessel intimal thickness will be excluded from the research. all patients and control groups underwent a complete extracranial and intracranial ultrasound assessment by 2 experienced neurovascular sonographers .the ultrasound examination was done at the neurovascular ultrasound laboratory in the neurology department, assiut university hospitals using a color-coded duplex ultrasound device philips hd5 (philips medical systems, nederland b.v.) for the carotid and vertebral arteries and for the intracranial arteries. intimal medial thickness (imt) of the common carotid artery (cca), peak systolic velocities (psvs) and end diastolic velocities (edvs) were measured in the common, internal, and external carotid arteries (cca, ica, eca) with l 3-12 mhz linear transducer probe and when stenosis was detected the velocities were measured at the maximally stenotic area. the intracranial arteries were evaluated in all patients with transcranial color-coded duplexsonography (tccs) with the use of a low-frequency (2- to 5-mhz) phased-array probe through the transtemporal acoustic bone window. the middle cerebral artery (mca), intracranial segment of vertebral artery (v4)and basilar artery (ba) were examined. peak systolic velocity (psv) and flow direction (antegrade or reversed) used for the diagnosis of any intracranial atherosclerotic disease (icad). the findings and the atherosclerotic changes in the extracranial and intracranial vessels were interpreted according to the internationally published data data will be analyzed using the computer program spss

Eligibility criteria:
inclusion criteria: * patient more than 18 years old * all patients fulfill the modified international criteria for behçet's disease exclusion criteria: * patients under 16 years old, * patients with hyperlipidemia, hypertension, diabetes mellitus and all other risk factors affecting blood vessel intimal thickness
emergency medical staff workload analysis

Conditions: Stress; Work Related Stress; PTSD; Mental Stress; Medical Emergencies

Summary: the aim of this study is to identify trauma determinants and leverage this understanding to develop solutions applicable to the prevention and treatment of ptsd among emergency medical personnel. by categorizing stimuli associated with traumatic professional experiences, the study aims to enhance existing therapeutic protocols through exposure therapy. the specific objectives are as follows: 1. analysis and characterization of occupational workloads among doctors and emergency medical personnel, focusing on the scale of burdens associated with ptsd symptoms. 2. development of categories for aggravating and potentially traumatizing stimuli within the medical staff of rescue teams. 3. examination of the feasibility of incorporating the obtained results into cognitive-behavioral therapy protocols. 4. assessment of the potential for implementing the results in solutions utilizing virtual reality technology. 5. formation of an interdisciplinary international research team.

background: data on the impact of workloads indicate that emergency medical personnel exposed to sudden threats to health or life are particularly vulnerable to the consequences of occupational stress. symptoms of post-traumatic stress disorder (ptsd) within this professional group significantly surpass the rates found in the general population. traumatic experiences encountered by medical staff may lead to a substantial decline in their mental health, as well as in their social and professional functioning. participants: several hundred medical doctors and emergency medical personnel from poland, ukraine, portugal and spain. research methodology: analysis of data collected through focused interviews, psychological scales, and questionnaires pertaining to burnout, stress, and mental health conditions.

Eligibility criteria:
inclusion criteria: * completed medical studies or emergency medical course * assistance in life-threatening conditions exclusion criteria: * intellectual disability * inability to self-complete the research questionnaires

Keywords: stress work-related stress trauma ptsd medical personnel
pharmacokinetic properties and effect of food on pharmacokinetic properties of the oral lafutidine tablets

Conditions: Chronic Gastritis

Summary: this study was to evaluate the pharmacokinetics of single and multiple doses of oral lafutidine tablets and the effect of food on pharmacokinetics in healthy chinese subjects. the tolerability and the effect of sex on the pharmacokinetic properties were also evaluated to acquire more pharmacokinetic information.

the study of single-dose was randomized, three-period, crossover. and in this study, 12 subjects were randomly assigned to 3 dose groups and received a single dose of 10mg, 20mg and 40mg lafutidine tablets. the washout period was 7 calendar days. in the multiple-dose, 12 subjects took lafutidine tablets of 10 mg twice a day for 6 consecutive days. in the food-effect study, 12 subjects were randomly assigned to 2 groups. one group received a single dose of 10mg lafutidine tablets under fasted condition, while the other were in fed condition. the drug administrations were separated by a wash-out period of seven calendar days. in each study group, the male and the female are both in half of the subjects. using a liquid chromatography tandem mass spectrometry (lc/ms/ms) method to determine the plasma concentration of lafutidine. pharmacokinetic parameters were calculated using the single compartment model.

Eligibility criteria:
inclusion criteria: * body mass index between19 and 24 kg/m2 * negative for hiv and hepatitis b * had no clinical important findings on health tests * thorax radiography and ecg with no abnormalities * normal blood pressure values * heart rate exclusion criteria: * any drug treatment within 2 weeks before starting the study * participation in another clinical study within the previous 3 months * alcoholism and smoking * pregnancy * breast-feeding * hypocalcemia * blood donation or participation in other clinical trials within 3 months before enrollment in the study * sitting blood pressure \ 140/100 mm hg * a ventricular rate \ 100 beats/min at rest

Keywords: lafutidine tablet pharmacokinetics food safety healthy subjects